Latest & greatest articles for prostate cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on prostate cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on prostate cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for prostate cancer

81. Care coordination interventions for prostate cancer survivors: a systematic review of the literature

Care coordination interventions for prostate cancer survivors: a systematic review of the literature Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

82. Systematic review and individual participant data meta-analyses of systemic treatments for hormone-sensitive metastatic prostate cancer

Systematic review and individual participant data meta-analyses of systemic treatments for hormone-sensitive metastatic prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO

83. Systematic review of the clinical, economic, utility and cost of illness evaluations in prostate cancer

Systematic review of the clinical, economic, utility and cost of illness evaluations in prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

84. The effect of multimodal prehabilitation interventions in men affected by prostate cancer on long-term physical, clinical and patient reported outcome measures: a systematic review

The effect of multimodal prehabilitation interventions in men affected by prostate cancer on long-term physical, clinical and patient reported outcome measures: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

85. Risk factors for TMPRSS2:ERG-defined prostate cancer: a systematic review

Risk factors for TMPRSS2:ERG-defined prostate cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

86. Prognostic role of lactate dehydrogenase in prostate cancer: a systematic review and meta-analysis

Prognostic role of lactate dehydrogenase in prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

87. Prognostic value of hemoglobin in metastatic hormone sensitive prostate cancer

Prognostic value of hemoglobin in metastatic hormone sensitive prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

88. Prognostic value of alkaline phosphatase in hormone sensitive prostate cancer: a systematic review and meta-analysis

Prognostic value of alkaline phosphatase in hormone sensitive prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

89. Body composition and prostate cancer risk: a systematic review of observational studies

Body composition and prostate cancer risk: a systematic review of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

90. Effects of first-line enzalutamide versus abiraterone plus prednisone on health-related quality-of-life in men with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis

Effects of first-line enzalutamide versus abiraterone plus prednisone on health-related quality-of-life in men with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

91. Evaluating the efficacy of bone modifying agents (BMAs) for treating bone metastasis originating from prostate cancer: an updated systemic review and network meta-analysis including RCT data from China

Evaluating the efficacy of bone modifying agents (BMAs) for treating bone metastasis originating from prostate cancer: an updated systemic review and network meta-analysis including RCT data from China Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

92. Multi-modal metastasis directed therapy in metastatic prostate cancer: a systematic review

Multi-modal metastasis directed therapy in metastatic prostate cancer: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

93. Association of glutathione s-transferase p1 (GSTP1) promoter methylation and the risk of prostate cancer: a systematic review and meta-analysis

Association of glutathione s-transferase p1 (GSTP1) promoter methylation and the risk of prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

94. A systematic review comparing multi-parametric MRI/transperineal biopsy and multi-parametric MRI/transrectal ultrasound guided biopsy in the diagnosis of prostate cancer

A systematic review comparing multi-parametric MRI/transperineal biopsy and multi-parametric MRI/transrectal ultrasound guided biopsy in the diagnosis of prostate cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

95. Comparison of MRI- or TRUS-informed prostate biopsy for prostate cancer diagnosis: a systematic review and meta-analysis

Comparison of MRI- or TRUS-informed prostate biopsy for prostate cancer diagnosis: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

96. Comparison of magnetic resonance imaging-stratified clinical pathway and systematic transrectal ultrasound (TRUS) guided biopsy pathway for detection of clinically significant prostate cancer: a systematic review and meta-analysis of randomized controlled

Comparison of magnetic resonance imaging-stratified clinical pathway and systematic transrectal ultrasound (TRUS) guided biopsy pathway for detection of clinically significant prostate cancer: a systematic review and meta-analysis of randomized controlled Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

97. Brachytherapy combined with or without hormone therapy for localized prostate cancer: a meta-analysis and systematic review

Brachytherapy combined with or without hormone therapy for localized prostate cancer: a meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

98. Body composition as predictive/prognostic parameter in prostate cancer patients: a systematic review and meta-analysis

Body composition as predictive/prognostic parameter in prostate cancer patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

99. The experience of patients with breast or prostate cancer recurrence: an integrative review

The experience of patients with breast or prostate cancer recurrence: an integrative review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

100. Reproducibility of bladder volume after water drinking in patients undergoing radiation therapy for prostate cancer: a systematic review and meta-analysis

Reproducibility of bladder volume after water drinking in patients undergoing radiation therapy for prostate cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO